Our company aims to manage the R&D process and marketing of drug candidates to provide a solution for neurodegenerative diseases.Learn more
Drug development of Q134R, which passed successful biochemical, cell based and in vivo (animal) screening and the following pre-clinical and Phase...Learn more
Drug candidate Q134R
The molecule is a proprietary clinical drug candidate that exerts multiple effects on different aspects of Alzheimer’s disease.Learn more
Q134R – Mechanisms of Action
Q134R is a strong cytoprotective agent: at nanomolecular range, it protects neuronal cells against ROS- (reactive oxygen species) and Abeta- (amyloid beta) induced neuronal death, and restores mitochondrial functioning.
Q134R restores memory impairment caused by scopolamine or Abeta oligomers, by modulation of the GABAA gated Cl- channels, specific for extrasynaptic signalling in neurogliaform cells, belonging to a specialized type of interneurons, which modulates memory formation.
Q134R has inhibitory effects on NFATs: a family of calcineurin- (CN) dependent transcription factors linked to the multiple pathologic hallmarks that emerge during AD. Numerous studies show that inhibition of CN/NFAT signalling leads to beneficial effects on amyloid pathology, neuroinflammation, neuronal viability, synaptic physiology, and cognitive function in mouse models of AD.
from the blog
Our latest News
New article on Q134R published in Aging Cell
Q134R: Small chemical compound with NFAT inhibitory properties improves behavioral performance and synapse function in mouse models of amyloid pathology Abstract...Read more
Promising new drug candidate can bring a breakthrough in the treatment of Alzheimer’s disease
An interview on the origin and development of our clinical candidate Q134R, on future plans of Aperus Pharma, and on the challenges of treating Alzheimer’s disease is...Read more
Interview with the CEO of Aperus Pharma
Interview with the László Puskás, PhD in the hungarian INNOTÉKA magazin. Click here to read the article (hungarian).Read more